Pasithea Therapeutics Corp. Statistics
Share Statistics
Pasithea Therapeutics Corp. has 102.49M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 102.49M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.59 and the forward PE ratio is null.
| PE Ratio | -0.59 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.4 |
| P/FCF Ratio | -0.73 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pasithea Therapeutics Corp..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.
| Current Ratio | 6.34 |
| Quick Ratio | 6.35 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is -68.05%.
| Return on Equity (ROE) | -0.68% |
| Return on Assets (ROA) | -0.61% |
| Return on Capital (ROIC) | -68.05% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.00M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | -16.01 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.82, so Pasithea Therapeutics Corp.'s price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 58 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | -648.45K |
| Operating Income | -15.98M |
| Net Income | -15.96M |
| EBITDA | -15.33M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -12.65 |
Balance Sheet
The company has 16.33M in cash and 81.68K in debt, giving a net cash position of 16.25M.
| Cash & Cash Equivalents | 16.33M |
| Total Debt | 81.68K |
| Net Cash | 16.25M |
| Retained Earnings | -35.32M |
| Total Assets | 18.64M |
| Working Capital | 9.12B |
Cash Flow
In the last 12 months, operating cash flow was -13.43M and capital expenditures -34.30K, giving a free cash flow of -12.85M.
| Operating Cash Flow | -13.43M |
| Capital Expenditures | -34.30K |
| Free Cash Flow | -12.85M |
| FCF Per Share | -10.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KTTAW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for KTTAW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 580.85 |
| Piotroski F-Score | 3 |